‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1
Digital health funding hit $7.4 billion in the first half of 2026, with megadeals absorbing nearly half of all capital. As AI becomes table stakes, founders and investors say the real differentiator is now domain expertise rather than technology.
Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer
Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers.
Neko Health Secures $700M to Support US Expansion
Neko’s Series C round was co-led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD.
Answers at the Speed of Thought: Healthcare Analytics in the Era of Agentic AI
We are moving into an era where we can finally converse with our data. We can ask, "Why are denials spiking in Region X?" or "Show me the safety profile of this cohort," and receive an answer, not a spreadsheet.
The Measurement Problem Behind Two Decades of Neurology Trial Failures
The FDA now treats continuous, real-time data sharing as a regulatory direction of travel rather than a theoretical future. The neurology field should pay close attention.